Notice for durvalumab (AstraZeneca Pty Ltd)
Active ingredients
durvalumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
concentrated injection
Indication
for the treatment of malignant mesothelioma
Therapeutic area
Oncology